CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM Article

Wefel, Jeffrey S, Won, Minhee, Lassman, Andrew et al. (2020). CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM . NEURO-ONCOLOGY, 22(Supplement_2), ii54-ii54. 10.1093/neuonc/noaa215.217

cited authors

  • Wefel, Jeffrey S; Won, Minhee; Lassman, Andrew; Stern, Yaakov; Wang, Tony; Aldape, Kenneth; Armstrong, Terri; Vogelbaum, Michael; Sulman, Erik; Moazami, Golnaz; Macsai, Marian; Gilbert, Mark; Bain, Earle; Blot, Vincent; Gan, Hui; Preusser, Matthias; Ansell, Peter; Samanta, Suvajit; Kundu, Madan; Seidel, Clemens; de Vos, Filip; Hsu, Sigmund; Cardona, Andres; Lombardi, Giuseppe; Bentsion, Dmitry; Peterson, Richard; Gedye, Craig; Lebrun-Frenay, Christine; Wick, Antje; Pugh, Stephanie; Curran, Walter; Mehta, Minesh

authors

publication date

  • November 9, 2020

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • Behavioral and Social Science
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Eye Disease and Disorders of Vision
  • Neurosciences

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • ii54

end page

  • ii54

volume

  • 22

issue

  • Supplement_2